The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is a huge mover today! About 80.31 million shares traded hands or 379.18% up from the average. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 44.02% since April 6, 2016 and is downtrending. It has underperformed by 45.97% the S&P500.
The move comes after 6 months negative chart setup for the $5.02 billion company. It was reported on Nov, 8 by Barchart.com. We have $13.45 PT which if reached, will make NYSE:VRX worth $451.80 million less.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage
Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 9 rate it a “Buy”, 2 “Sell”, while 12 “Hold”. This means 39% are positive. Valeant Pharmaceuticals Intl has been the topic of 75 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Rodman & Renshaw on Wednesday, March 16. Mizuho downgraded the stock to “Underperform” rating in Monday, March 21 report. The rating was maintained by Mizuho on Thursday, January 7 with “Neutral”. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, March 16. The firm earned “Market Perform” rating on Thursday, October 22 by BMO Capital Markets. Deutsche Bank initiated the stock with “Hold” rating in Tuesday, September 20 report. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Hold” rating by Canaccord Genuity on Wednesday, March 2. The stock has “Sector Perform” rating given by IBC on Monday, November 30. The company was maintained on Wednesday, March 16 by Morgan Stanley. The firm has “Buy” rating by Mizuho given on Tuesday, October 27.
According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”
Insitutional Activity: The institutional sentiment decreased to 0.86 in Q2 2016. Its down 0.06, from 0.92 in 2016Q1. The ratio is negative, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Stoneridge Invest Partners Limited last reported 138,637 shares in the company. Prescott Grp Management Ltd Company last reported 0.32% of its portfolio in the stock. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0.02% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Teewinot Capital Advisers Lc last reported 50,100 shares in the company. Truepoint Inc has 0.06% invested in the company for 25,000 shares. Lonestar Mngmt Lc has 0.27% invested in the company for 50,000 shares. The Florida-based Raymond James Services Advisors Incorporated has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Moreover, State Of New Jersey Common Pension Fund D has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 20,000 shares. Fil Limited has 0% invested in the company for 16,671 shares. Silver Point Cap Ltd Partnership last reported 0.99% of its portfolio in the stock. Okumus Fund Ltd, a New York-based fund reported 4.24M shares. Van Eck Assoc Corporation owns 212,797 shares or 0.02% of their US portfolio. Clearbridge accumulated 0.07% or 2.94 million shares. Clinton Grp Inc holds 176,927 shares or 0.16% of its portfolio. Hbk Limited Partnership accumulated 0.11% or 653,353 shares.
Insider Transactions: Since June 9, 2016, the stock had 2 buys, and 0 insider sales for $5.04 million net activity. On Thursday, June 9 PAPA JOSEPH C bought $4.94 million worth of the stock or 202,000 shares. KARABELAS ARGERIS N bought $98,600 worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Thursday, August 11.
More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Fool.com which released: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” on November 08, 2016, also Fool.com with their article: “Another Month, Another 27% Decline for Valeant Pharmaceuticals Intl. Inc. in …” published on November 07, 2016, Profitconfidential.com published: “Valeant Pharmaceuticals Intl Inc: Did VRX Stock Just Bottom?” on November 03, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Fool.com and their article: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” published on November 01, 2016 as well as Investorplace.com‘s news article titled: “Why Valeant Pharmaceuticals Intl Inc (VRX), Allergan plc Ordinary Shares (AGN …” with publication date: November 02, 2016.
VRX Company Profile
Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.